52669-92-8

Basic information

• Product Name: 4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine hydrochloride
• Synonyms: 4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine hydrochloride;1-[4-Oxo-4-(4-fluorophenyl)butyl]-4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine;4-[[4-(4-Chlorophenyl)-1,2,3,6-tetrahydropyridin]-1-yl]-1-(4-fluorophenyl)-1-butanone;HPTP;4-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-1-(4-fluorophenyl)-1-butanone;Protein tyrosine phosphatase, receptor type, S;PTPRS;PTPsigma/PTPRS Active human
• CAS NO: 52669-92-8
• Molecular Formula: C₂₁H₂₁ClFNO
• Molecular Weight: 357.85
• Mol File: 52669-92-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 496.8°Cat760mmHg
• Flash Point: 254.3°C
• Appearance: /
• Density: 1.196
• Vapor Pressure: 5.22E-10mmHg at 25°C
• Refractive Index: 1.576
• Storage Temp.: -70°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine hydrochloride(52669-92-8)
• EPA Substance Registry System: 4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine hydrochloride(52669-92-8)

Safety Data

• Hazardous Substances Data: 52669-92-8(Hazardous Substances Data)

Usage

Description

4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine hydrochloride is a complex organic compound with a chemical structure that features a tetrahydropyridine ring, chlorophenyl and fluorophenyl groups, and an oxobutyl chain. It is a derivative of haloperidol, a commonly used antipsychotic medication.

Uses

Used in Pharmaceutical Industry:
4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine hydrochloride is used as an active pharmaceutical ingredient for the treatment of various psychiatric disorders. Its application is based on its ability to modulate dopamine receptors in the brain, which helps in managing symptoms such as hallucinations, delusions, and agitation associated with conditions like schizophrenia and bipolar disorder.
Used in Research and Development:
In the field of neuroscience and pharmacology, this compound serves as a valuable research tool for studying the mechanisms of action of antipsychotic drugs. It is used to investigate the interactions between neurotransmitters and their receptors, as well as to develop new drugs with improved efficacy and reduced side effects.
Used in Metabolite Studies:
4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine hydrochloride is also used in metabolite studies to understand the biotransformation processes of haloperidol in the human body. This knowledge is crucial for assessing the safety and efficacy of the drug, as well as for identifying potential neurotoxic metabolites like Haloperidol pyridinium (HPP+) that may be associated with adverse effects.

InChI:InChI=1/C21H21ClFNO/c22-19-7-3-16(4-8-19)17-11-14-24(15-12-17)13-1-2-21(25)18-5-9-20(23)10-6-18/h3-11H,1-2,12-15H2

Upstream product

• 52-86-8 haloperidol 
• 3874-54-2 4-(4-fluorophenyl)-4-oxo-n-butyl chloride 
• 39512-49-7 4-(4-chlorophenyl)-4-hydroxypiperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 30005-58-4 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine 
• 235109-63-4 4-(4-chloro-phenyl)-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 
• 106-39-8 bromochlorobenzene 

Relevant articles and documents

Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from: Mycobacterium tuberculosis to overcome kanamycin resistance

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a deadly bacterial disease. Drug-resistant strains of Mtb make eradication of TB a daunting task. Overexpression of the enhanced intracellular survival (Eis) protein by Mtb confers resistance to the second-line antibiotic kanamycin (KAN). Eis is an acetyltransferase that acetylates KAN, inactivating its antimicrobial function. Development of Eis inhibitors as KAN adjuvant therapeutics is an attractive path to forestall and overcome KAN resistance. We discovered that an antipsychotic drug, haloperidol (HPD, 1), was a potent Eis inhibitor with IC50 = 0.39 ± 0.08 μM. We determined the crystal structure of the Eis-haloperidol (1) complex, which guided synthesis of 34 analogues. The structure-activity relationship study showed that in addition to haloperidol (1), eight analogues, some of which were smaller than 1, potently inhibited Eis (IC50 ≤ 1 μM). Crystal structures of Eis in complexes with three potent analogues and droperidol (DPD), an antiemetic and antipsychotic, were determined. Three compounds partially restored KAN sensitivity of a KAN-resistant Mtb strain K204 overexpressing Eis. The Eis inhibitors generally did not exhibit cytotoxicity against mammalian cells. All tested compounds were modestly metabolically stable in human liver microsomes, exhibiting 30-60% metabolism over the course of the assay. While direct repurposing of haloperidol as an anti-TB agent is unlikely due to its neurotoxicity, this study reveals potential approaches to modifying this chemical scaffold to minimize toxicity and improve metabolic stability, while preserving potent Eis inhibition. This journal is

Antifungal Compositions

Provided herein are antifungal compositions and methods of use thereof. The antifungal compositions include an antifungal agent and an antipsychotic agent or an antihistamine. The methods of use thereof include administering a composition including an antifungal agent and an antipsychotic or an antihistamine to a plant or animal in need thereof.